Consensus Statement: PDF OnlyFerris S. H.; Hofeldt, G. T.; Carbone, G.; Masciandaro, P.; Troetel, W. M.; Imbimbo, B. P.Alzheimer Disease & Associated Disorders: April-June 1999 - p 88-90 Buy Abstract Summary Two patients meeting the criteria for probable Alzheimer disease (AD) who were participating in a phase 3 clinical program with eptastigmine, a cholinesterase inhibitor, committed suicide. The first patient committed suicide by a self-inflicted gunshot wound to the head. The second patient committed suicide by jumping from a 19th story window. These two patients shared several clinical features with those found in the literature: being at the early stages of the disease, having a high level education, with preserved insight, having access to firearms, and being aware of not responding to pharmacological treatment. © 1999 Lippincott Williams & Wilkins, Inc.